Verve Therapeutics, Inc. (VERV): Price and Financial Metrics


Verve Therapeutics, Inc. (VERV): $36.34

0.19 (+0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VERV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VERV Stock Price Chart Interactive Chart >

Price chart for VERV

VERV Price/Volume Stats

Current price $36.34 52-week high $56.18
Prev. close $36.15 52-week low $10.70
Day low $35.49 Volume 597,700
Day high $37.43 Avg. volume 876,172
50-day MA $34.65 Dividend yield N/A
200-day MA $26.12 Market Cap 2.19B

Verve Therapeutics, Inc. (VERV) Company Bio


Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.


VERV Latest News Stream


Event/Time News Detail
Loading, please wait...

VERV Latest Social Stream


Loading social stream, please wait...

View Full VERV Social Stream

Latest VERV News From Around the Web

Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.

5 Top Stocks Cathie Wood Is Buying This Week

There's a new Ark fund in town, and its name is the ARK Venture Fund.

Eddie Pan on InvestorPlace | September 30, 2022

The Top 5 Stocks Cathie Wood Is Buying This Week

Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL.

Eddie Pan on InvestorPlace | September 23, 2022

Verve Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following upcoming investor conferences: Guggenheim 2022 Nantucket Therapeutics Conference (fireside chat) on Wednesday, September 28, 2022, at 7:30 a.m. ET in Nantucket, Mass.;Jefferies Cell and Genetic Medicine Summit 2022

Yahoo | September 22, 2022

Cathie Wood Goes Shopping for Biotech: 3 Stocks She Just Bought

The founder and CEO of ARK Investment Management is buying up drugmaker stocks like they're going out of style.

Yahoo | September 22, 2022

Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the clearance of its Clinical Trial Authorisation (CTA) application by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for VERVE-101 as a potential treatment for patients with heterozygous familial hypercholesterolemia (He

Yahoo | September 21, 2022

Read More 'VERV' Stories Here

VERV Price Returns

1-mo -9.01%
3-mo 71.17%
6-mo 85.31%
1-year -21.61%
3-year N/A
5-year N/A
YTD -1.44%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4717 seconds.